Author

Hank Kaplan

Observed institution: Swedish Medical Center

OpenAlex ID: A5111745902

Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

2014 · John W. Park, Minetta C. Liu, et al. · Cancer Research · 25

Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

2015 · Denise M Wolf, Christina Yau, et al. · Cancer Research

Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

2015 · Christina Yau, Denise M Wolf, et al. · Cancer Research

Works count: 3

Citation count: 25

H-index: 1

I10-index: 1